Alivus Life Sciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-.

Powered by Capital Market - Live News

Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25.

For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY.

On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25.

Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.

Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

Powered by Capital Market - Live News

Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25.

For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY.

On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25.

Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.

Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

Powered by Capital Market - Live News

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are among the other gainers in the BSE's 'A' group today, 21 January 2025.

Alivus Life Sciences Ltd surged 6.82% to Rs 1178.4 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 11436 shares were traded on the counter so far as against the average daily volumes of 5071 shares in the past one month.

Avantel Ltd spiked 6.10% to Rs 143.6. The stock was the second biggest gainer in 'A' group. On the BSE, 3.06 lakh shares were traded on the counter so far as against the average daily volumes of 1.35 lakh shares in the past one month.

Sunteck Realty Ltd soared 5.43% to Rs 517.7. The stock was the third biggest gainer in 'A' group. On the BSE, 1.38 lakh shares were traded on the counter so far as against the average daily volumes of 12899 shares in the past one month.

Spandana Sphoorty Financial Ltd advanced 4.99% to Rs 366.95. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.38 lakh shares were traded on the counter so far as against the average daily volumes of 1.94 lakh shares in the past one month.

Jai Corp Ltd gained 4.22% to Rs 157. The stock was the fifth biggest gainer in 'A' group. On the BSE, 71599 shares were traded on the counter so far as against the average daily volumes of 2.64 lakh shares in the past one month.

Powered by Capital Market - Live News

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-.

Powered by Capital Market - Live News

Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25.

For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY.

On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25.

Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.

Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

Powered by Capital Market - Live News

Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25.

For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY.

On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25.

Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.

Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

Powered by Capital Market - Live News

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are among the other gainers in the BSE's 'A' group today, 21 January 2025.

Alivus Life Sciences Ltd surged 6.82% to Rs 1178.4 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 11436 shares were traded on the counter so far as against the average daily volumes of 5071 shares in the past one month.

Avantel Ltd spiked 6.10% to Rs 143.6. The stock was the second biggest gainer in 'A' group. On the BSE, 3.06 lakh shares were traded on the counter so far as against the average daily volumes of 1.35 lakh shares in the past one month.

Sunteck Realty Ltd soared 5.43% to Rs 517.7. The stock was the third biggest gainer in 'A' group. On the BSE, 1.38 lakh shares were traded on the counter so far as against the average daily volumes of 12899 shares in the past one month.

Spandana Sphoorty Financial Ltd advanced 4.99% to Rs 366.95. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.38 lakh shares were traded on the counter so far as against the average daily volumes of 1.94 lakh shares in the past one month.

Jai Corp Ltd gained 4.22% to Rs 157. The stock was the fifth biggest gainer in 'A' group. On the BSE, 71599 shares were traded on the counter so far as against the average daily volumes of 2.64 lakh shares in the past one month.

Powered by Capital Market - Live News